Nusinersen therapy changed the natural course of spinal muscular atrophy type 1: What about spine and hip?
Journal of Children's Orthopaedics · 2024-06 · 18 (3) · 322-330
DOI: 10.1177/18632521241235028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Children's Orthopaedics, online erschienen am 08.03.2024. Verfasst von Niyazi Erdem Yasar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Orthopaedic Surgery, Ankara Bilkent Children's Hospital, Ankara, Turkey. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Purpose
Spinal muscular atrophy type 1 has a devastating natural course and presents a severe course marked by scoliosis and hip subluxation in nonambulatory patients. Nusinersen, Food and Drug Administration-approved spinal muscular atrophy therapy, extends survival and enhances motor function. However, its influence on spinal and hip deformities remains unclear.
Methods
In a retrospective study, 29 spinal muscular atrophy type 1 patients born between 2017 and 2021, confirmed by genetic testing, treated with intrathecal nusinersen, and had registered to the national electronic health database were included. Demographics, age at the first nusinersen dose, total administrations, and Children’s of Philadelphia Infant Test of Neuromuscular Disorders scores were collected. Radiological assessments included parasol rib deformity, scoliosis, pelvic obliquity, and hip subluxation.
Results
Mean age was 3.7 ± 1.1 (range, 2–6), and average number of intrathecal nusinersen administration was 8.9 ± 2.9 (range, 4–19). There was a significant correlation between Children’s of Philadelphia Infant Test of Neuromuscular Disorders score and the number of nusinersen administration ( r = 0.539, p = 0.05). The correlation between Children’s of Philadelphia Infant Test of Neuromuscular Disorders score and patient age ( r = 0.361) or the time of first nusinersen dose ( r = 0.39) was not significant ( p = 0.076 and p = 0.054, respectively). While 93.1% had scoliosis, 69% had pelvic obliquity, and 60.7% had hip subluxation, these conditions showed no significant association with patient age, total nusinersen administrations, age at the first dose, or Children’s of Philadelphia Infant Test of Neuromuscular Disorders scores.
Conclusion
Disease-modifying therapy provides significant improvements in overall survival and motor function in spinal muscular atrophy type 1. However, progressive spine deformity and hip subluxation still remain significant problems in the majority of cases which would potentially need to be addressed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pediatric Orthopaedic Surgery, Ankara Bilkent Children's Hospital, Ankara, Turkey.
- Department of Orthopaedics and Traumatology, University of Health Sciences, Ankara Bilkent City Hospital, Ankara, Turkey.
- Department of Radiology, University of Health Sciences, Ankara Bilkent City Hospital, Ankara, Turkey.
- Ministry of Health, General Directorate of Health Information Systems, Ankara, Turkey.
- Department of Biostatistics, Faculty of Medicine, University of Ankara, Ankara, Turkey.
- Ministry of Health, Ankara, Turkey.
Zitieren
APA
Yasar, N. E., Ozdemir, G., Uzun Ata, E., Ayvali, M. O., Ata, N., Ulgu, M., Dumlupınar, E., Birinci, S., Bingol, I., & Bekmez, S. (2024). Nusinersen therapy changed the natural course of spinal muscular atrophy type 1: What about spine and hip?. Journal of Children's Orthopaedics, 18(3), 322-330. https://doi.org/10.1177/18632521241235028
Vancouver
Yasar NE, Ozdemir G, Uzun Ata E, Ayvali MO, Ata N, Ulgu M, et al. Nusinersen therapy changed the natural course of spinal muscular atrophy type 1: What about spine and hip?. Journal of Children's Orthopaedics. 2024;18(3):322-330. doi:10.1177/18632521241235028
BibTeX
@article{Yasar2024,
author = {Yasar, Niyazi Erdem and Ozdemir, Guzelali and Uzun Ata, Elif and Ayvali, Mustafa Okan and Ata, Naim and Ulgu, Mahir and Dumlupınar, Ebru and Birinci, Suayip and Bingol, Izzet and Bekmez, Senol},
title = {Nusinersen therapy changed the natural course of spinal muscular atrophy type 1: What about spine and hip?},
journal = {Journal of Children's Orthopaedics},
year = {2024},
volume = {18},
number = {3},
pages = {322--330},
doi = {10.1177/18632521241235028}
}
EUVIMED